More broadly, the unique molecular classes which emerged across IDH1/2-mutant astrocytoma with distinct survival outcomes reinforce the biological variability amongst these gliomas and the need to consider individual patient profiles. The gene discussed is IDH1; the disease is central nervous system cancer.